Novartis delivered a strong Q2 2025 with double-digit sales growth and core margin expansion. We advanced our pipeline reaching milestones for both late-stage and emerging assets, and our key launches are accelerating with consistent strong execution. We upgraded our full-year 2025 core operating income guidance and remain confident in our mid- to long-term growth outlook. https://lnkd.in/gEX5dEY3 #NVSQ22025
Info
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- Website
-
http://www.novartis.com
Externer Link zu Novartis
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Basel, Baselstadt
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand und Gene and cell therapy
Orte
Beschäftigte von Novartis
-
David Yee
Head Portfolio Systems & Capabilities, Enterprise Portfolio Insights, Strategy & Growth at Novartis
-
Rodolfo Garcia de Alba Cassaigne
Regional Category Procurement Director, US Marketing Agencies
-
Kelley Dallas Priddy, M.S.
Medical Sales Specialist | Award Winner | Drives Sales Performance Through Analytics & Business Planning
-
Jennifer Ma
Updates
-
Last week, the Novartis Biomedical Research site in Cambridge, Mass., was buzzing with energy as leading minds from biotech and healthcare came together to reimagine medicine through collaboration. In an inspiring discussion on the future of biopharma, Novartis leaders underlined the importance of external partnerships in driving forward innovation, complementing our powerful internal science and discovery work and unlocking greater value. Moderated by Atlas Venture's Bruce Booth, the panel featuring Fiona H. Marshall, Ronny Gal and Susanne Kreutz explored global trends, the transformative role of AI, and China’s rising influence in drug discovery. Together, they demonstrated how a flexible, creative approach to partnerships can drive breakthrough science, fuel innovation, and advance patient care—ultimately shaping the future of medicine. To learn more about our approach to partnering, visit: https://lnkd.in/ggeAqmp9 #Biotech #Innovation #Collaboration #VC #PharmaLeadership #Novartis
-
-
We’ve just announced a new malaria breakthrough for newborns. But did you know Novartis has been innovating against the odds in malaria for more than 30 years? Swipe left to get the facts and learn why we’re just getting started. European & Developing Countries Clinical Trials Partnership (EDCTP) Medicines for Malaria Venture
-
We asked when you last saw something small make a big difference, and your stories said it all. From a quick check-in to a moment of encouragement, from being challenged to being supported – what stands out isn’t the size of the gesture, but the impact it has. The ripple effect of a kind word, a thoughtful gesture, or a fresh perspective can’t be underestimated. These are the moments that help us make each other extraordinary and create positive change for patients. Imagine if we never underestimated the power of a simple action. #ImagineIf #ThriveTogether
-
When was the last time you saw something small make a big difference? Maybe it was a quick word of encouragement, a fresh idea, or someone stepping in at just the right moment. These seemingly small actions often create the space for others to thrive – and in our work of reimagining medicine, they can be the spark that leads to positive change for patients. So we’d love to hear from you – what’s one small moment that has stayed with you? Share your story in the comments. #ImagineIf #ThriveTogether
-
-
Today we announce a new breakthrough in malaria. Novartis has received approval for the first malaria medicine for newborn babies and young infants. The positive decision from Swissmedic under a special global health initiative is now expected to lead to rapid approvals across eight African countries. But we’re not done. Building on our three-decade track record developing malaria medicines, we are going further. Together with our partners, we are harnessing our unique capabilities as an innovative medicines company to develop four new antimalarial compounds with the potential to combat drug resistance. This is part of nearly USD 490 million in funding for global health R&D since 2021, which has helped to create the industry’s No. 1 pipeline of treatments for malaria and neglected diseases. Medicines for Malaria Venture | European & Developing Countries Clinical Trials Partnership (EDCTP)
-
A 1950’s scientific study on London bus workers revealed a major link between physical activity and heart health. We are continuing to build on this legacy by investing in research to help address cardiovascular diseases on a global scale. Read the full story on Live Magazine https://lnkd.in/gvkv-zWT #CVD #Novartis
-
We have been using “mini-hearts” to advance our research in cardiovascular diseases. Developed from induced pluripotent stem cells (IPSC), these mini-hearts will aid our research by accelerating the development of new treatments and improving our understanding of heart biology. See which diseases we are researching with this pioneering technology by reading the full article https://lnkd.in/g3kaCwyw #CVD #Novartis
-
What do you want to be known for? Curiosity. Kindness. Reliability. The answers may be different, but they all point to something deeper. At Novartis, we believe that how we show up matters. And when we take a moment to ask ourselves what we want to be known for, we begin to shape how we lead, how we connect, and how we grow – together. Curious how we’re bringing that mindset to life? Explore how we’re living our culture: https://lnkd.in/gm4YhHE7
-
At Novartis, we're pushing boundaries to tackle some of the most complex health challenges facing patients today. From pioneering breakthroughs in cancer and cardiovascular care to expanding access through innovative collaborations—we’re bridging science and patient needs to create meaningful change. Recently, we had the opportunity to join visionary thinkers and innovators at Aspen Ideas: Health 2025, where we engaged in conversations that challenge the norms, spark collaboration, and inspire forward-thinking solutions. Check out our behind the scenes look!
Novartis at Aspen Ideas: Health 2025
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Novartis
Insgesamt 2 Finanzierungsrunden
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdkapital nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
2.487.694.394,00 $